Home›Clinical trials›A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Enrolling now · NCT06897475

A study testing whether an investigational Lilly medicine (LY3457263) from Lilly can lower blood sugar and help with weight.

What this means for you

Who can join
Adults 18 to 75, have type 2 diabetes, BMI 27+.
What you take
LY3457263, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 1.8 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 2Sponsor Eli Lilly and CompanyDrug LY3457263Class GLP-1 RASites 25 USEnrollment target 240

What this study is for

Primary condition: Type 2 Diabetes.

Full scientific study title: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide.

Who can join

Age18 to 75SexAnyBMI27 or higher

Adults 18 to 75, have type 2 diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have type 2 diabetes
  • Have HbA1c >=7.5% to <=10.5% at screening
  • Have a body mass index (BMI) of >=27 kilograms per square meter (kg/m2) at screening
  • Have had a stable body weight for the three months prior to screening
  • On stable treatment dose of one of the following incretins for at least three months prior to screening:

Key exclusion criteria

  • Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma
  • Have a prior or planned surgical treatment for obesity
  • Have any of the following cardiovascular conditions within three months prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)

Where this study is enrolling

This trial has 25 sites across 14 states. Contact a site coordinator directly to start screening.

Arizona1 site
  • Helios Clinical Research - Phoenix
    Phoenix, Arizona
    480-372-5996
California1 site
  • Wolverine Clinical Trials
    Santa Ana, California
    714-617-2426
Florida2 sites
  • Renstar Medical Research
    Ocala, Florida
    352-629-5800
  • Oviedo Medical Research
    Oviedo, Florida
    407-977-2705
Georgia4 sites
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia
    770-696-4541
  • Physicians Research Associates
    Lawrenceville, Georgia
    678-252-2375
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia
    470-317-3604
  • North Georgia Clinical Research
    Woodstock, Georgia
    678-494-5735
Idaho1 site
  • Elite Clinical Trials
    Rexburg, Idaho
    208-356-8977
Indiana1 site
  • Investigators Research Group
    Brownsburg, Indiana
    317-852-8280
New Jersey1 site
  • Clinical Research of Philadelphia
    Pennington, New Jersey
    215-676-6696
New York3 sites
  • NYC Research INC
    Long Island City, New York
    516-574-9232
  • Richmond University Medical Center
    Staten Island, New York
    718-818-2430
  • Southgate Medical Group
    West Seneca, New York
    716-712-1004
North Carolina2 sites
  • Lucas Research, Inc.
    Morehead City, North Carolina
    252-222-5700
  • Shelby Clinical Research
    Shelby, North Carolina
    980-552-9230
Ohio1 site
  • Providence Health Partners-Center for Clinical Research
    Dayton, Ohio
    937-297-8994
Oklahoma1 site
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma
    405-701-8999
Pennsylvania1 site
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania
    724-220-5281
Texas5 sites
  • Juno Research
    Houston, Texas
    713-779-5494
  • Southern Endocrinology Associates
    Mesquite, Texas
    214-693-0904
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas
    512-334-3505
  • Consano Clinical Research, LLC
    Shavano Park, Texas
    210-545-4900
  • Texas Valley Clinical Research
    Weslaco, Texas
    956-431-8090
Washington1 site
  • Eastside Research Associates
    Redmond, Washington
    425-869-6828

Timeline

Started enrolling: 2025-03-28. Expected completion: 2027-01. Last updated on ClinicalTrials.gov: 2026-05-22.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.